Both Inhibitex's INX-189 and Idenix's IDX184 are so-called nucleoside "nuc" polymerase inhibitors -- otherwise known as the hottest and most sought after class of hepatitis C drugs currently in development. Gilead spent $11 billion to acquire Pharmasset and its nuc PSI-7977. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.